Together, the in vivo data from both PDAC (Figure 5) and CRC (Figure 6) tumours strongly support that the FL118's target, DDX5, can act as a biomarker and target for predicting PDAC and CRC tumour sensitivity to FL118 treatment. The gene discussed is DDX5; the disease is neoplasm.